Merck Past Earnings Performance
Past criteria checks 5/6
Merck's earnings have been declining at an average annual rate of -0.5%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 9.1% per year. Merck's return on equity is 31.5%, and it has net margins of 22%.
Key information
-0.5%
Earnings growth rate
-0.2%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 9.1% |
Return on equity | 31.5% |
Net Margin | 22.0% |
Next Earnings Update | 31 Oct 2024 |
Recent past performance updates
Recent updates
Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)
Oct 15Merck Is At Support And Should Go Higher (Technical Analysis)
Oct 07Merck Appears Ready To Return To June Highs (Technical Analysis)
Sep 14Merck's Change To Profit Guidance Provides An Opportunity
Sep 01Merck: Buy This Bargain Before It's Gone
Aug 12Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 01Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins
Jul 31Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE
Jul 24Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Jul 18Merck: Positive Developments, But Watch The Q2 Earnings
Jul 12Revenue & Expenses Breakdown
How Merck makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 62,480 | 13,736 | 9,847 | 17,739 |
31 Mar 24 | 61,403 | 2,306 | 9,839 | 18,592 |
31 Dec 23 | 60,115 | 365 | 9,884 | 18,342 |
30 Sep 23 | 59,314 | 4,608 | 9,820 | 12,677 |
30 Jun 23 | 58,311 | 3,111 | 9,934 | 12,881 |
31 Mar 23 | 57,869 | 13,030 | 9,851 | 12,433 |
31 Dec 22 | 59,283 | 14,519 | 9,669 | 11,918 |
30 Sep 22 | 58,974 | 15,322 | 10,119 | 11,923 |
30 Jun 22 | 57,169 | 16,641 | 9,776 | 10,940 |
31 Mar 22 | 53,978 | 13,910 | 9,489 | 10,515 |
31 Dec 21 | 48,704 | 12,345 | 9,403 | 11,942 |
30 Sep 21 | 46,131 | 5,908 | 9,260 | 10,725 |
30 Jun 21 | 43,906 | 3,665 | 8,845 | 10,678 |
31 Mar 21 | 41,857 | 4,793 | 8,669 | 10,339 |
31 Dec 20 | 41,518 | 4,519 | 8,569 | 10,564 |
30 Sep 20 | 42,438 | 9,492 | 8,812 | 9,079 |
30 Jun 20 | 43,906 | 9,070 | 9,200 | 8,818 |
31 Mar 20 | 46,312 | 9,399 | 9,700 | 8,990 |
31 Dec 19 | 39,121 | 5,690 | 8,829 | 8,594 |
30 Sep 19 | 45,970 | 9,314 | 9,604 | 8,489 |
30 Jun 19 | 44,367 | 9,362 | 9,586 | 7,997 |
31 Mar 19 | 43,073 | 8,399 | 9,467 | 8,084 |
31 Dec 18 | 42,294 | 6,220 | 9,587 | 9,254 |
30 Sep 18 | 41,729 | 3,347 | 9,541 | 9,251 |
30 Jun 18 | 41,259 | 1,341 | 9,554 | 11,680 |
31 Mar 18 | 40,725 | 1,579 | 9,449 | 11,182 |
31 Dec 17 | 40,122 | 2,394 | 9,560 | 9,845 |
30 Sep 17 | 39,804 | 2,845 | 9,615 | 9,427 |
30 Jun 17 | 40,016 | 5,086 | 9,612 | 6,916 |
31 Mar 17 | 39,929 | 4,346 | 9,713 | 7,035 |
31 Dec 16 | 39,807 | 3,920 | 9,313 | 6,921 |
30 Sep 16 | 39,907 | 5,492 | 9,193 | 6,849 |
30 Jun 16 | 39,444 | 5,133 | 9,312 | 6,828 |
31 Mar 16 | 39,385 | 4,614 | 9,776 | 6,518 |
31 Dec 15 | 39,498 | 4,442 | 9,799 | 6,613 |
30 Sep 15 | 39,765 | 10,781 | 10,262 | 6,727 |
30 Jun 15 | 40,249 | 9,850 | 10,756 | 6,644 |
31 Mar 15 | 41,398 | 11,168 | 10,818 | 6,685 |
31 Dec 14 | 42,237 | 11,920 | 11,172 | 6,532 |
30 Sep 14 | 43,075 | 5,385 | 11,501 | 6,435 |
30 Jun 14 | 43,550 | 5,614 | 11,304 | 6,544 |
31 Mar 14 | 43,626 | 4,516 | 11,511 | 6,774 |
31 Dec 13 | 44,033 | 4,404 | 11,672 | 7,123 |
Quality Earnings: MRK has high quality earnings.
Growing Profit Margin: MRK's current net profit margins (22%) are higher than last year (5.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRK's earnings have declined by 0.5% per year over the past 5 years.
Accelerating Growth: MRK's earnings growth over the past year (341.5%) exceeds its 5-year average (-0.5% per year).
Earnings vs Industry: MRK earnings growth over the past year (341.5%) exceeded the Pharmaceuticals industry 13%.
Return on Equity
High ROE: MRK's Return on Equity (31.5%) is considered high.